title: [Effect of metabolic therapy on the course of heart failure in patients after myocarditis complicated with systemic connecting tissue diseases].
abstract: In the course of observation over 40 patients after an old myocarditis against general systemic diseases of connective tissue who had been given a pharmacotherapy regarding main disease and a chronic heart failure, additionally Vazonat (campaign of "Olajnfarm", Latvia), preparation of the myocardial cytoprotection was prescribed in a therapeutic dose of 500 mg per day. Vazonat inclusion in basic therapy during 1 month was accompanied by improvement of a clinical condition of the patients, reduction of heart failure signs, and improvement of life quality.
authors.forename: A V
authors.initials: AV
authors.lastname: Kuriata
authors.forename: I L
authors.initials: IL
authors.lastname: Karavanskaia
authors.forename: N A
authors.initials: NA
authors.lastname: Pavlichenko
mesh_terms: D000328:Adult; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003240:Connective Tissue Diseases / Q000150:complications* / Q000378:metabolism; D004452:Echocardiography; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009205:Myocarditis / Q000150:complications* / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D002316:Cardiotonic Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate